Form 4: BioMarin Director Elizabeth Anderson Receives Stock Grant

Director Elizabeth M. Anderson acquired 7,490 restricted stock units in BioMarin Pharmaceutical Inc. on June 2, 2026.

Summary

• Director Elizabeth M. Anderson was granted 7,490 restricted stock units (RSUs) by BioMarin Pharmaceutical Inc.
• The transaction occurred on June 2, 2026.
• Following this grant, the director's total beneficial ownership of common stock increased to 41,940 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation.

Positives

• The grant of restricted stock units aligns the director's interests with those of long-term shareholders.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that routine equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure director retention and alignment with shareholder value.

Comparison to Industry Standards

• The issuance of restricted stock units to directors is a common practice among mid-to-large cap pharmaceutical companies to incentivize long-term oversight.
• The transaction size is consistent with standard director compensation packages for companies of BioMarin's market capitalization.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard equity-based compensation for a director.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Keywords

BioMarin, BMRN, Form 4, Insider Trading, Director Compensation, Restricted Stock Units